A presentation delivered by IPPOSI CEO, Derick Mitchell at the University College Dublin PharmTox Society event on Clinical Trials in Ireland on March 6th, 2017
A presentation delivered by IPPOSI CEO, Derick Mitchell at the Irish Brain Council-Neurological Allinace of ireland joint event in the Science Gallery, Dublin on March 7th, 2017.
Patients at the Centre for Health Research – Patient, Carer and Public Invol...Nowgen
"Patients at the Centre for Health Research –
Patient, Carer and Public Involvement in NICE Decision-Making", presented by Victoria Thomas, NICE, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
A presentation delivered by IPPOSI CEO, Derick Mitchell at the University College Dublin PharmTox Society event on Clinical Trials in Ireland on March 6th, 2017
A presentation delivered by IPPOSI CEO, Derick Mitchell at the Irish Brain Council-Neurological Allinace of ireland joint event in the Science Gallery, Dublin on March 7th, 2017.
Patients at the Centre for Health Research – Patient, Carer and Public Invol...Nowgen
"Patients at the Centre for Health Research –
Patient, Carer and Public Involvement in NICE Decision-Making", presented by Victoria Thomas, NICE, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Involving People: Patients, Participants & Consumers in U.K.Cancer Research (...Nowgen
Involving People: Patients, Participants & Consumers in U.K.Cancer Research, presented by Richard Stephens at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patient involvement in clinical research and long term conditions -what can b...Nowgen
"Patient involvement in clinical research and long term conditions -what can be achieved by working in partnership", presented by Dr. J. Paul Schofield, ABPI, at EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
INVOLVE perspectives on learning and development (Sarah Buckland, INVOLVE)Nowgen
"INVOLVE perspectives on learning and development", presented by Sarah Buckland, INVOLVE, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patient involvement in medicines development – the views of patients and key ...Nowgen
"EUPATI – EU: An overview", held by Bella Starling & Suzanne Parsons (EUPATI / Nowgen) at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
UCD Rare Disease Module 2017 - Dr Derick Mitchell - March 28th 2017ipposi
Medical students taking the elective course in rare diseases are provided a number of patient perspectives throughout the module. This is what IPPOSI presented in 2017.
Bringing the patient voice into GSK for educational, awareness and patient ce...Nowgen
"Bringing the patient voice into GlaxoSmithKline for educational, awareness and patient centred decisions within medicine development", presented by Kay Warner, Global Manager, Focus on the Patient, GlaxoSmithKline, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
PPPI - the involvement of patients or people in the design and development o...ipposi
Dr Jean Saunders, University of Limerick, and IPPOSI Board Member (Science) presents at the 5th World Congress on Advanced Clinical Trials and Clinical Research on public and patient involvement in clinical trials.
Involving People: Patients, Participants & Consumers in U.K.Cancer Research (...Nowgen
Involving People: Patients, Participants & Consumers in U.K.Cancer Research, presented by Richard Stephens at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patient involvement in clinical research and long term conditions -what can b...Nowgen
"Patient involvement in clinical research and long term conditions -what can be achieved by working in partnership", presented by Dr. J. Paul Schofield, ABPI, at EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
INVOLVE perspectives on learning and development (Sarah Buckland, INVOLVE)Nowgen
"INVOLVE perspectives on learning and development", presented by Sarah Buckland, INVOLVE, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patient involvement in medicines development – the views of patients and key ...Nowgen
"EUPATI – EU: An overview", held by Bella Starling & Suzanne Parsons (EUPATI / Nowgen) at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
UCD Rare Disease Module 2017 - Dr Derick Mitchell - March 28th 2017ipposi
Medical students taking the elective course in rare diseases are provided a number of patient perspectives throughout the module. This is what IPPOSI presented in 2017.
Bringing the patient voice into GSK for educational, awareness and patient ce...Nowgen
"Bringing the patient voice into GlaxoSmithKline for educational, awareness and patient centred decisions within medicine development", presented by Kay Warner, Global Manager, Focus on the Patient, GlaxoSmithKline, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
PPPI - the involvement of patients or people in the design and development o...ipposi
Dr Jean Saunders, University of Limerick, and IPPOSI Board Member (Science) presents at the 5th World Congress on Advanced Clinical Trials and Clinical Research on public and patient involvement in clinical trials.
IPPOSI CEO Derick Mitchell delivered a presentation on Dec 6th 2019 at the Digital health Conference, organised as part of the Royal College of Physicians, Ireland
A presentation delivered by Derick Mitchell, IPPOSI CEO at the event to celebrate International Clinical Trials Day on May 10th, 2018 in the Mansion House, Dublin, organised by HRB-CRCI.
Rare Diseases SA has been actively improving the quality of life for those impacted by Rare Diseases over the last 5 years.
Our key focus areas have remained advocacy, patient navigation and community engagement, and through these strategic objectives we have successfully managed to see positive impact in our community.
From the development of over 80 patient connect points, to the implementation of a mobile app, RDSA has ensured patients remain supported and connected whilst the organization remains focused on our advocacy efforts.
The successful roll-out of our Rare Assist service has also seen a reduction in out of pocket costs for patients in the private sector.
We have attached our 5 year impact report which demonstrates some of the impact our work has had within our community. We have also included our programme overview of the Rare Assist Programme.
We would love to have your feedback on these reports, as well as feedback on the following questions:
1. What interest do you have with our organisation?
2. What is your current opinion on our work?
3. How would you like to stay informed about what we do?
4. What motivates you to stay connected with us?
Should you have any questions for us, we would love to hear from you.
Kind Regards
Kelly du Plessis
CEO -Rare Diseases South Africa
info@rarediseases.co.za
Research managers jan 14th, 2016 - ipposi presentationipposi
Irish Platform for Patient Organisations, Science & Industry - the importance of patient involvement in research, and patient training on medicines development and health research.
Patient Engagement for Data Science, Technology & EngineeringCHICommunications
Learn the necessities and relationship between patient engagement and data science, engineering and technology.
Presented by Trish Roche, CHI's Knowledge Translation Practice Lead, this presentation is geared towards professionals in data science looking to hone their skills in patient engagement.
EU Clinical Trials Regulation - IPPOSI perspectiveipposi
IPPOSI CEO, Dr Derick Mitchell delivered a presentation on the EU Clinical Trials Regulation from the patients' perspective at the 20th International Conference on Pharmaceutical Medicine, Athens, Greece.
This talk was given to the Alberta Cancer Foundation in Calgary, January 2015. It looks at different approaches to public involvement in research funding by UK charities. It also includes some updated slides on the results of the Breaking Boundaries review.
Challenges in Implementing Innovations in Midwifery Practice An Overviewijtsrd
Midwifery Nursing and women’s health emphasize the caring of women who are in need of care in their reproductive life as well nurturing in the journey from the womb to the beautiful world. As a midwife, she would be a great specialist to care the women from menarche to menopause. On other aspect, this branch of nursing provides optimum and comprehensive care in prenatal, natal and postpartum for the mothers and to get their newborns healthy and charming. Innovations, research findings are many, in this era. Unfortunately, in the health care system in a challenging facet to implement these innovative practices in midwifery. We the midwives to think innovatively to implement the findings and research evidences as a style of quality care to the woman and child. Mrs. Jasmi Manu "Challenges in Implementing Innovations in Midwifery Practice: An Overview" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-6 , October 2020, URL: https://www.ijtsrd.com/papers/ijtsrd35698.pdf Paper Url: https://www.ijtsrd.com/medicine/nursing/35698/challenges-in-implementing-innovations-in-midwifery-practice-an-overview/mrs-jasmi-manu
Let's talk people in research sept 2014Simon Denegri
This slide-deck covers the main components of current NIHR approaches towards public involvement in research; its ongoing strategic review of the area and; its current policy towards engaging patients through the NHS.
Utilización de la evidencia cualitativa para mejorar la inclusión de las pref...GuíaSalud
Tercera intervención de la Mesa 1 de la Jornada científica GuíaSalud 2017: La implicación de pacientes en el desarrollo de GPC. Una estrategia necesaria para mejorar la toma de decisiones. Simon Lewin
Tripartite dimension of interaction of patients, regulators and industry (Jan...jangeissler
Tripartite dimension of interaction of patients, regulators and industry, presented by Jan Geissler as a scene-setting presentation at the EUPATI Workshop on the interaction of patients, regulators and industry on 20 July 2016 in Berlin
Romana Hasnain-Wynia: Incorporating the Patient’s Perspective in ResearchNIHACS2015
Romana Hasnain-Wynia, MS, PhD, is the Director of the Addressing Disparities Program at the Patient-Centered Outcomes Research Institute (PCORI). During the conference, she gave a presentation on incorporating the patient’s perspective in research.
his is the first in a series of interactive webinars designed to build capacity in the basic principles of knowledge translation and implementation science.
WATCH-ON DEMAND: https://goo.gl/hnp8gi
Similar to RCSI Research Summer School - Dr Derick Mitchell - June 7th 2017 (20)
Derick Mitchell_Biobanking from the patient perspective.pdfipposi
IPPOSI CEO Derick Mitchell presented the patient perspective on biobanking at the 2023 WECAN Academy for Cancer Patient Advocates on July 2nd, 2023 in Frankfurt, Germany.
Mental Health - Leading the data sharing charge with a rights-based approachipposi
Frankie Prendergast's (Digital Health Applications Programme Manager in St Patrick's Mental Health Services) presentation on health information at the 2023 IPPOSI Conference.
Muiris O'Connor, Assistant Secretary of the Department of Health, presented key government updates on health information at the 2023 IPPOSI Conference Building a Data Sharing Health Sector in Ireland.
Clinical Workflow for Capture of Patient Registry Dataipposi
Clare Harney, Managing Director of HD Health, gave a lightning presentation on managing data for patient registries at the 2023 IPPOSI Conference on Building a Data Sharing Health Sector in Ireland.
Patient Centricity in Value-based healthcare, Sept 2022ipposi
IPPOSI CEO Derick Mitchell delivered a presentation as part of the RCSI Value Based Healthcare Webinar on Patient Centricity on Sept 18th, 2022.
The Future of Value Based Healthcare in Ireland webinar series is run by The RCSI Healthcare Outcomes Research Centre, Janssen Sciences Ireland UC and Novartis Ireland.
2022 World Day Brain Event - IPPOSI Presentationipposi
Laura Kavanagh, Research and Advocacy Manager in IPPOSI, gave a presentation on World Brain Day 2022 at an event hosted by the Neurological Alliance of Ireland.
In October 2020, IPPOSI published a membership engagement survey on its draft 4-year strategy. This slide deck captures the summary results of the survey.
On 14 November 2019, our Research and Advocacy Manager, Laura Kavanagh delivered this presentation on ‘the Drug Iceberg report’ to participants at the Retina Roundtable. The Roundtable kicked off a three-day conference around the topic of ‘Evidence Generation for Access to Innovative Therapies’. IPPOSI was asked to outline the access to medicine challenges faced by patients in Ireland, including the health technology assessment (HTA) and post-HTA processes.
Overview of the Haemophilia Patient Record System. Presentation by Declan Noone, President, European Haemophilia Consortium, originally presented at the IPPOSI Annual Conference 2019
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
3. “The perfect is the enemy of the good”
http://metro.co.uk/2015/05/19/intermarche-campaign-celebrating-ugly-fruit-and-veg-is-brilliant-5204782/
4. Incorporating the patient voice
• Hierarchical Rhetoric
• ‘Walking the walk’ at the highest possible level
Challenges:
• Decision-makers never want to change their processes
• Patients are not trained in policy, R&D dialogue
• Many patient orgs are not focused on policy/R&D issues
5. IPPOSI? Who?IPPOSI
A patient-led organisation
that works with patients,
government, industry,
& science to put patients at the
heart of health innovation
6. Our Priorities
20
Actively advocate for improved + equitable
patient access to Health Innovation
Promote meaningful patient involvement in
Health Research and Policy
9. Conclusions
Public Survey
• Limited understanding of how one
can participate
(donating blood/tissue, medical info.)
• Ethical concerns
• Unnecessary Risk
IPPOSI patient members (anecdotal)
(➕)
• Access to innovative medicines &
technologies
• Improved quality of care
(➖)
• Benefit : Risk
• Randomization
• Compassionate Use
• Ending of trial
10. Educated Patient Communities
IPPOSI Training for Members
• Clinical Research
• Health Technology Assessment
• Pharmaceutical Code of Practices
• Health Informatics (coming soon!)
EUPATI produces Expert Patients on Medicines R&D
• Training & Education
• Disseminates through national platforms
11. Areas covered by the Patients’ Academy
1.Medicines development process from research to approval
2. Personalized and predictive medicine
3.Drug safety and risk/benefit assessment of medicines
4. Pharmaco-economics, health economics and health technology assessment
5. Design and objectives of clinical trials
(& roles of stakeholders)
6. Patients roles & responsibilities in medicines
development
…and NOT:
develop indication-
or therapy-specific
information!
14. Roles change as a result of EUPATI
course
- creating patient leaders
Role Before EUPATI After
Member of patient organisation, not actively involved 17% 2%
Active role in a patient organisation 62% 71%
Leadership role in a patient organisation 62% 71%
Employee of a patient organisation 25% 23%
Volunteer role in a patient organisation 60% 67%
Presenting at conferences, workshops etc. 63% 83%
Advising a pharmaceutical company 13% 44%
Advising a regulatory agency 21% 42%
Advising a reimbursement agency 4% 8%
EUPATI Fellows are increasingly taking leadership roles and are engaging with
pharma, regulators and HTA bodies.
Role changes also imply identity shifts.
16. Irish Patient Education Programme
• 2017 Pilot
• 20 places for patients / patient advocates
• Pilot modules
• Clinical Trials
• Regulatory Aspects incl. Benefit:Risk
• Health Technology Assessment
17. Will it make any difference?
Patient involvement can:
• Provide a different perspective
• Make language + content of research information clear and accessible
• Help to ensure research methods are acceptable and sensitive
• Help ensure that research uses outcomes that are important to the public
• Help increase participation in research in general
18. Building a new Irish healthcare environment
2016 – Mental Health Local Recovery Groups
(HSE)
2016 - Patient Narrative Project on Person-
centered care (CSPD-HSE, IPPOSI)
2017 - National Patient Experience Survey in
Hospitals (HIQA, HSE, DoH)
2017 - National Clinical Effectiveness
Committee – PPI Values (DoH, NCEC)
2017 –Personas for Electronic Health Records
(eHealth Ireland)
19. Building a new Irish health research environment
2014 - PPI paper - Irish Health Research Forum
2016/17 - PPI reviewers - HRB
2017 - PPI Ignite Funding – HRB + IRC
2017 – Scientific Advice – Patient Involvement – HPRA
Health Information & Patient Safety Bill?
Human Tissue Bill??
20. Take Home Messages
Patient involvement can improve research quality
Education + Training of both patients & researchers is key
Support patient networks, communities & spread the word!
@IPPOSI www.ipposi.ie
Editor's Notes
Last year I presented on IPPOSI, and was joined by Joan Jordan – MS Ireland & EUPATI trainee, now fellow
This year?
Regulators and funders are doing it!
A patient-led platform that provides a structured way of facilitating interaction between patients, government, industry, science and academia to put patients at the heart of policy and medicines development. In pursuit of this we hold workshops, discussion groups, training days and conferences on policy, legislation and regulation around the development of new medicines, products, devices and diagnostics for unmet medical needs.
We recognise that establishing a functional biobanking or indeed an eHealth system that has the confidence of the Irish public is a challenge that cannot be rushed, particularly in light of the (potential) uses of patient information.
It is our experience, in the area of clinical research, that patients are willing to donate samples, and share their data1 provided they receive in advance a clear explanation of:
what the data will be used for;
under what circumstances; and
by whom it will be accessed.
Everyone thought they were guinea pigs. But through the process of explaining what clinical research is, what it is for, they embraced the concept and were motivated to get involved. Same could be said for ehealth…
Patients don’t have a problem with IP of a sample, so long a you are open and honest about how you are going to use it..
Until we did the piece of research, we didn’t know.
Everyone thought they were guinea pigs
Through the process of explaining what clinical research is, what it is for, they embraced the concept and were motivated to get involved.
Same for Connected health…
The premise underlying PPI is that is improves the research relevance and quality, the accepability and feasability of research conduct, and improves the likelihood of uptake of results
provide a different perspective - even if you are an expert in your field, your knowledge and experience will be different to the experience of someone who is using the service or living with a health condition
make the language and content of information such as questionnaires and information leaflets clear and accessible help to ensure that
the methods proposed for the study are acceptable and sensitive to the situations of potential research participants
In addition to improving relevance and quality of research, it ensures that research is influenced by broader principles of citizenship, accountability and transparency.
The Clinical Strategy & Programmes Division of the HSE initiated the Patient Narrative Project to partner with users of healthcare services in the design and delivery of these services.
The Patient Narrative Project is a three phase project to progress to partnership working
listened to the experiences of people who have had to use multiple health services over time or at one time and through the words of the service users and caregivers developed a set of statements that clearly articulate what users of the Irish health service expect from services and staff.
In addition a definition of person-centred co-ordinated care that is written not just for the experts, but for patients, people, families and carers
The goal is that the descriptors + definition of what good care and support that is centred around the needs and preferences of the service user/patient looks and feels like for people will be adopted nationally. They will be used to guide policy, strategy and design, and act as a guide to what teams at local levels should be aiming to achieve practically, in their efforts to integrate services around patient, family and carer needs.
There are three themes of descriptors:
‘Care for me’ focused on the direct relational experience with healthcare professionals.
‘Care I am confident in’ refers to the actual experience of care in terms of skills, quality, accountability and continuity of care.
‘Care in my journey through healthcare’ represents care that is holistic, accessible at a time needed and takes account of the world of the person and their carer beyond what was traditionally considered health care, but where health has an impact (e.g. education, working life)
Health services in Ireland are including patient voices in decision making to a greater extent now than ever before. The HSE’s National Strategy for Service User Involvement 2008-2013, the National Patients Forum, the National Patient Experience Survey and the IPPOSI-led Patient Narrative project are examples. Furthermore, the Department of Health is working with IPPOSI and other relevant patient-led organisations in areas such as rare diseases, dementia and others.
Training required to get the expertise required to contribute to research & development projects
Emerging patient-centered movement
Not a trump card for justifying/tolerating pseudoscience
Patient-centered does not mean facilitating and legitimizing the provision of unproven therapies and “magical thinking”
It does not mean providing patients with unscientific, placebo-inducing treatments
It does mean, among other things, respecting the patient enough to provide an honest assessment of what the best available evidence says. Healthcare providers are legally required to do so through informed consent process